

TABLE II
REPORTED DISEASE RATES¹
(CASES PER 100,000 POPULATION)
2007-2016

DISEASE	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
AMEBIASIS	0.7	0.7	0.7	0.7	0.6	0.4	0.8	1.0	1.4	1.8
AMEBIC CNS ²	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ANTHRAX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ASCARIASIS	0.0	NR	NR	NR	NR	NR	NR	NR	NR	NR
BABESIOSIS	0.0	0.0	0.0	0.0	NR ³	NR	NR	NR	NR	NR
BOTULISM, FOODBORNE	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BOTULISM, INFANT ⁴	1.7	1.7	1.7	1.7	0.2	1.0	2.0	1.0	2.0	1.0
BOTULISM, WOUND	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BOTULISM, OTHER	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
BRUCELLOSIS	0.2	0.1	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.1
CALIFORNIA ENCEPHALITIS VIRUS ⁵	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CAMPYLOBACTERIOSIS	16.5	14.2	9.4	9.8	9.1	6.7	7.9	6.5	5.9	7.1
CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)	4.4	3.2	NA ⁶	NR	NR	NR	NR	NR	NR	NR
CHAGAS	0.1	0.1	0.1	0.1	NR	NR	NR	NR	NR	NR
CHICKENPOX (VARICELLA)	4.7	5.4	6.0	7.0	9.1	9.9	10.9	17.9	32.2	42.0
CHIKUNGUNYA ⁷	0.1	0.2	0.4	NR	NR	NR	NR	NR	NR	NR
CHOLERA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CONTAMINATED SHARPS INJURY ⁸	-	-	-	-	-	-	-	-	-	-
CRYPTOSPORIDIOSIS	2.6	2.7	1.5	1.5	1.1	1.9	1.4	1.7	13.7	1.0
CYCLOSPORIASIS	0.5	1.1	0.7	1.3	0.2	0.1	0.0	0.0	0.0	0.0
CYSTICERCOSIS	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DENGUE	0.2	0.1	0.1	0.4	0.1	0.0	0.1	0.1	0.1	0.1
DIPHTHERIA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EASTERN EQUINE ENCEPHALITIS VIRUS ⁵	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ECHINOCOCCOSIS	0.0	NR	NR	NR	NR	NR	NR	NR	NR	NR
EHRLICHIOSIS/ANAPLASMOSIS	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1
ENCEPHALITIS, NONARBOVIRAL	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.0
ESCHERICHIA COLI, SHIGA TOXIN-PRODUCING (STEC)	3.6	2.2	2.2	2.3	1.9	1.9	1.4	1.0	1.4	0.9
ESCHERICHIA COLI (E. COLI) O157:H7	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
E. COLI, SHIGA POSITIVE NON-O157	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
E. COLI, SHIGA POSITIVE NOT SEROGROUPED	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
HAEMOPHILUS INFLUENZAE, INVASIVE	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
HANTAVIRUS INFECTION	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HANTAVIRUS PULMONARY SYNDROME	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HEMOLYTIC UREMIC SYNDROME	0.0	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0
HEPATITIS A, ACUTE	0.5	0.5	0.4	0.4	0.5	0.5	0.5	0.7	1.1	1.1
HEPATITIS B, ACUTE	0.6	0.6	0.4	0.5	0.6	0.8	1.6	1.7	2.3	3.1
HEPATITIS B, PERINATAL ⁹	0.2	0.1	0.4	0.2	0.5	0.5	0.2	0.1	1.0	0.4
HEPATITIS C, ACUTE	0.1	0.2	0.0	0.1	0.2	0.1	0.1	0.1	0.2	0.3
HEPATITIS D, ACUTE	NR	NR	NR	NR	0.0	0.0	0.0	0.0	0.0	0.0
HEPATITIS E, ACUTE	0.1	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0
INFLUENZA-ASSOCIATED PEDIATRIC MORTALITY ¹⁰	0.1	0.2	0.3	0.2	0.2	0.2	0.1	0.8	0.1	0.2
INFLUENZA, NOVEL A ¹¹	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
JAPANESE ENCEPHALITIS VIRUS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
LEGIONELLOSIS	1.0	1.1	0.9	0.6	0.6	0.4	0.5	0.5	0.3	0.5
LEISHMANIASIS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
LISTERIOSIS	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.2	0.3
LYME DISEASE	0.3	0.2	0.1	0.3	0.3	0.3	0.6	1.1	0.6	0.4
MALARIA	0.6	0.4	0.4	0.3	0.4	0.4	0.4	0.4	0.4	0.5
MEASLES	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
MENINGITIS, ASEPTIC	NR	NR	NR	NR	4.4	5.0	6.6	7.5	7.2	8.9
MENINGITIS, BACTERIAL/OTHER	NR	NR	NR	NR	1.5	1.6	1.8	1.7	2.1	2.0
MENINGOCOCCAL INFECTION	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.3	0.2
MULTIDRUG-RESISTANT ACINETOBACTER (MDR-A)	3.6	3.5	NA ¹²	NR	NR	NR	NR	NR	NR	NR
MUMPS	0.7	0.1	0.1	0.0	0.1	0.3	0.5	0.2	0.1	0.1
NOVEL CORONAVIRUS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PERTUSSIS	4.6	5.4	9.4	14.8	8.4	3.7	11.2	13.5	8.4	4.4
PLAQUE	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
POLIOMYELITIS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PRION DISEASES	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Q FEVER	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.1	0.0

DISEASE	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007
RABIES, HUMAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
RELAPSING FEVER	NR	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
RUBELLA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
RUBELLA, CONGENITAL SYNDROME ¹³	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SALMONELLOSIS	20.9	20.7	18.7	18.4	18.9	20.2	19.4	16.0	22.9	14.8
SHIGELLOSIS	15.5	20.3	10.0	8.9	7.3	9.8	10.3	9.3	19.2	9.9
SMALLPOX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SPOTTED FEVER GP RICKETTSIOSSES	0.3	0.2	0.3	0.3	0.3	0.2	0.1	0.1	0.3	0.2
ST LOUIS ENCEPHALITIS VIRUS ⁵	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
STREPTOCOCCUS, GROUP A	2.5	2.6	2.2	1.6	1.3	1.6	1.4	1.3	1.8	1.2
STREPTOCOCCUS, GROUP B	6.2	6.1	4.9	3.9	3.9	3.5	3.3	2.7	2.4	1.8
STREPTOCOCCUS PNEUMONIAE	6.2	6.1	5.7	6.4	5.8	6.2	7.5	7.9	7.8	5.9
TAENIASIS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TETANUS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TRICHINOSIS	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TULAREMIA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TYFHOID FEVER	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1
TYPHUS, MURINE	1.3	1.2	1.1	0.8	1.0	1.1	0.5	0.8	0.6	0.7
VENEZUELAN EQUINE ENCEPHALITIS VIRUS ⁵	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	NR	0.0
VIBRIO PARAHAEMOLYTICUS	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1
VIBRIO VULNIFICUS	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
VIBRIO, OTHER/UNSPECIFIED	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1
VIRAL HEMORRHAGIC FEVER	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
VISA	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
VRSA	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
WESTERN EQUINE ENCEPHALITIS VIRUS ⁵	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
WEST NILE FEVER	0.4	0.3	0.5	0.3	7.1	0.0	0.0	0.1	0.1	0.4
WEST NILE NEUROINVASIVE DISEASE	0.9	0.7	0.9	0.4	0.0	0.1	0.3	0.4	0.2	0.7
YELLOW FEVER	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
YERSINIOSIS	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0
ZIKA VIRUS DISEASE	1.1	0.0	NR							

¹ Population data is from the Department of State Health Services, Center for Health Statistics <http://www.dshs.state.tx.us/chs/popdat/popup.shtm>.

For years 2008 (24,326,974) and 2009 (24,782,302), population estimates are used since projected population data was not captured in annual reports for those years.

For years 2007 (23,936,227), 2010 (25,373,947), 2011 (25,883,999), 2012 (26,403,743), 2013 (26,932,619), 2014 (27,470,110), 2015 (27,695,284) and 2016 (28,240,245), projected population is used.

² Amebic central nervous system (CNS) infections include primary amebic meningoencephalitis (PAM) caused by *Naegleria fowleri* and CNS infections caused by other amebae. Counts by organism and year: *Naegleria fowleri* - 2-2007, 1-2008, 1-2010, 1-2013; *Balamuthia mandrillaris* - 1-2007, 1-2010, 1-2014; *Acanthamoeba healyi* - 1-2012.

³ Condition not reportable (NR) in Texas.

⁴ Infant botulism rates are calculated using the population under 1 year of age.

⁵ Since 2007, includes both neuro-invasive and non-neuroinvasive cases. California encephalitis/meningitis refers to all California serogroup viruses.

California serogroup includes California encephalitis, Keystone, snowshoe hare, and trivittatus viruses. All cases of Jamestown Canyon and La Crosse should be reported separately.

⁶Data is no available (NA) for the whole year. MDR-A and CRE were not officially reportable until April 21st, 2014.

⁷ Includes both neuro-invasive and non-neuroinvasive cases.

⁸ Rates are not available. The referent population, health care workers at Texas governmental entities, is unknown.

⁹ Perinatal hepatitis B cases are defined as infants >1 month of age through 24 months of age who were born in the US to HBsAg positive mothers. The rates were calculated using the population under 2 years of age, which approximates this cohort.

¹⁰ Influenza-associated pediatric mortality cases are calculated using the population under 18 years of age.

¹¹ Novel Influenza A is a count of the number of novel strains detected by CDC in isolates from Texas. Although initial spread is tracked, subsequent cases are not reportable and a population rate cannot be calculated.

¹²Data is no available (NA) for the whole year. MDR-A and CRE were not officially reportable until April 21st, 2014.

¹³ Congenital rubella rates are calculated using the population under 1 year of age.